|
|||||
|
|
Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents |
|
| Authors: | Silvia N. Tenembaum |
| Affiliation: | 1. Laboratoire Interdisciplinaire Carnot de Bourgogne, UMR 6303 CNRS-Université de Bourgogne, 9 Avenue Alain Savary, BP47870, F-21078 DIJON Cedex, France;2. Institut FEMTO-ST, UMR 6174 CNRS, Université de Franche-Comté, ENSMM, UTBM, 32 Avenue de l''observatoire, F-25044, BESANCON Cedex, France;1. Department of Gastroenterology & Hepatology, Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia;2. Centre of Physical Activity and Nutrition (C-PAN) Research, School of Exercise and Nutrition Science, Deakin University, Burwood, Victoria, Australia |
| Abstract: | Paediatric multiple sclerosis (MS) accounts for up to 5% of all MS cases. No therapies have been formally approved for paediatric patients with MS. However, there is published experience on the use of disease modifying therapies in children and adolescents with MS.Neuromyelitis optica (NMO) is an autoimmune inflammatory disease preferentially targeting the optic nerves and spinal cord. This devastating disease usually requires preventive therapy with a range of immunosuppressive medications. There are limited studies informing the use of these medications in children with NMO. This review provides a comprehensive analysis of the published literature on therapeutic interventions in children and adolescents with MS and NMO. |
| Keywords: | Multiple sclerosis Neuromyelitis optica Childhood Disease modifying therapies Immunosuppressive agents |
| 本文献已被 ScienceDirect 等数据库收录！ | |